Clinical Trial Results:
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of SAB378 (15 mg t.i.d.) administered orally for 4 weeks to patients with postherpetic neuralgia
Summary
|
|
EudraCT number |
2004-003913-18 |
Trial protocol |
GB SE DE |
Global completion date |
05 Jun 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Oct 2016
|
First version publication date |
12 Oct 2016
|
Other versions |
|
Summary report(s) |
CSAB378A2201_NovCTR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.